VIP for Sale — Research Peptide VIP | Real Peptides

VIP for Sale — Research Peptide VIP | Real Peptides

Research-grade Vasoactive Intestinal Peptide (VIP) isn't a commodity product. It's a 28-amino-acid neuropeptide with six critical disulfide bonds that degrade under improper handling, turning a functional compound into an inactive fragment chain. The difference between effective VIP research and null results often comes down to synthesis precision and post-production cold-chain management, not dosage or protocol design.

We've worked with research institutions across immunology, neuroscience, and pulmonary research labs for years. The gap between published VIP mechanisms and reproducible bench results almost always traces back to peptide purity and storage failures that occur before the first injection ever happens.

What does it mean when VIP is listed as 'for sale' for research purposes?

VIP for sale in research contexts refers to Vasoactive Intestinal Peptide supplied as lyophilised powder with documented purity analysis, intended exclusively for in vitro or animal model studies under institutional oversight. These preparations are not FDA-approved drugs. They are research-grade biochemical tools synthesized to exact amino acid sequences for laboratory investigation of VIP's immunomodulatory, neuroprotective, and bronchodilatory pathways. Real Peptides supplies VIP at >98% purity with batch-specific HPLC verification.

The term 'for sale' in peptide research markets doesn't imply clinical use or human administration. VIP for research is manufactured under good laboratory practice (GLP) standards by specialized peptide synthesis facilities, not pharmaceutical manufacturing plants. The distinction matters: research peptides undergo amino-acid sequencing and mass spectrometry verification but are not subject to FDA clinical trial oversight or GMP production requirements that govern prescription medications.

This article covers VIP's biological mechanism of action, why synthesis precision directly impacts research reproducibility, what cold-chain failures do to peptide stability, and how to evaluate supplier claims when VIP is offered for sale.

Vasoactive Intestinal Peptide Mechanism and Research Applications

Vasoactive Intestinal Peptide (VIP) is a 28-amino-acid neuropeptide originally isolated from porcine intestine in 1970 by Said and Mutt. It functions as both a neurotransmitter in the central and peripheral nervous systems and a potent immunomodulator, binding to VPAC1 and VPAC2 receptors (G-protein-coupled receptors) distributed across smooth muscle, immune cells, and neural tissue. VIP receptor activation triggers cyclic AMP (cAMP) elevation, which downstream modulates T-cell differentiation, cytokine profiles, and bronchial smooth muscle relaxation.

The immunomodulatory effects are what drive most current research interest. VIP shifts T-helper cell balance from pro-inflammatory Th1 and Th17 phenotypes toward regulatory T-cells (Tregs), reducing interleukin-17 (IL-17) and tumor necrosis factor-alpha (TNF-α) while elevating interleukin-10 (IL-10), an anti-inflammatory cytokine. This mechanism has been investigated in animal models of rheumatoid arthritis, inflammatory bowel disease, sepsis, and multiple sclerosis. Conditions where dysregulated immune activation drives pathology. A 2008 study published in PNAS demonstrated that VIP administration reduced disease severity scores in murine collagen-induced arthritis by 60% compared to vehicle controls, correlating with decreased synovial inflammation and Th17 infiltration.

VIP's neuroprotective properties are mediated through similar cAMP-dependent pathways in astrocytes and microglia. In models of traumatic brain injury and stroke, VIP administration has shown reduced neuronal apoptosis and microglial activation. Research published in Journal of Neuroinflammation (2014) found VIP treatment post-injury reduced infarct volume by 38% in rodent stroke models and decreased pro-inflammatory microglial markers (CD68, iNOS) at 72 hours post-injury.

Pulmonary research applications focus on VIP's bronchodilator effects and anti-fibrotic signaling in lung tissue. VIP relaxes airway smooth muscle through cAMP-mediated inhibition of myosin light-chain kinase, making it a candidate compound for asthma and chronic obstructive pulmonary disease (COPD) models. It also inhibits transforming growth factor-beta (TGF-β) signaling in fibroblasts, which drives collagen deposition in pulmonary fibrosis. A phase II clinical trial evaluating inhaled VIP analogs in sarcoidosis patients (published in Chest, 2001) showed improved forced vital capacity (FVC) and reduced inflammatory markers, though the trial was small and results have not led to FDA approval of any VIP-based therapy.

When evaluating VIP for sale, research teams must verify the supplier provides sequence-confirmed peptides, not truncated or scrambled analogs. Even single amino acid substitutions or oxidation of methionine residues at positions 17 or 28 can reduce receptor binding affinity by more than 50%. This is why batch-specific mass spectrometry and HPLC chromatograms should accompany every research-grade VIP shipment.

Synthesis Precision and Purity Standards in Research Peptides

VIP synthesis follows solid-phase peptide synthesis (SPPS) protocols using Fmoc (9-fluorenylmethoxycarbonyl) chemistry, where amino acids are sequentially coupled to a resin-bound growing chain. For a 28-residue peptide like VIP, synthesis precision becomes exponentially critical. Each coupling step carries a 1–3% risk of incomplete reaction or side-chain deprotection error, meaning cumulative purity loss compounds across 28 cycles. A 98% per-step coupling efficiency yields approximately 57% crude purity after full-length synthesis; further purification via reverse-phase HPLC is mandatory to reach >98% final purity.

The six disulfide bonds in VIP are not present in the linear synthesized chain. Proper folding requires controlled oxidation conditions post-cleavage, typically using air oxidation in dilute aqueous solution at pH 8.0–8.5 or chemical oxidants like iodine. Improper oxidation leads to misfolded or scrambled disulfide pairings, creating peptide conformations that retain full molecular weight (detectable by mass spec) but show drastically reduced receptor binding. This is the single most common failure mode in low-quality VIP preparations. The amino acid sequence is correct, but the three-dimensional structure is non-functional.

When VIP is offered for sale by research suppliers, purity documentation should include: (1) HPLC chromatogram showing a single dominant peak at >98% area under curve, (2) mass spectrometry confirming the expected molecular weight (3326.77 Da for human VIP), and (3) amino acid analysis verifying residue composition. Suppliers who provide only a certificate of analysis (CoA) with a stated purity percentage but no raw analytical data are red flags. There is no independent verification of synthesis accuracy.

Real Peptides synthesizes VIP in small batches with exact sequencing verified through electrospray ionization mass spectrometry (ESI-MS) and analytical HPLC before lyophilisation. Every batch ships with a CoA containing the HPLC chromatogram and mass spec trace specific to that production lot. This is standard practice among legitimate peptide suppliers but is not universal. Budget suppliers often pool batches or provide generic CoAs copied across multiple SKUs, which eliminates traceability.

Lyophilisation (freeze-drying) extends VIP shelf life by removing water, which otherwise accelerates hydrolysis and oxidation. Lyophilised VIP stored at −20°C in sealed vials shows less than 5% degradation over 24 months, per stability data published by peptide manufacturers. Once reconstituted with bacteriostatic water or sterile saline, stability drops sharply. Reconstituted VIP should be aliquoted into single-use volumes and stored at −80°C to minimize freeze-thaw cycles, which fragment peptide bonds. At 2–8°C (standard refrigerator), reconstituted VIP degrades approximately 10–15% per week, making multi-week storage impractical without freezing.

Cold-Chain Handling and Storage Protocols for Peptide Stability

VIP degrades through three primary pathways: oxidation of methionine residues, deamidation of asparagine and glutamine residues, and hydrolysis of peptide bonds. All three are temperature-dependent, accelerating exponentially above 8°C. A single 24-hour exposure to ambient temperature (20–25°C) can reduce VIP bioactivity by 20–40%, even if the peptide is subsequently refrozen. The damage is irreversible because structural changes (oxidized methionine, cleaved bonds) cannot be reversed by cooling.

Shipping VIP without cold-chain management is a failure point many researchers underestimate. Standard ground shipping in summer months can expose packages to cargo hold temperatures exceeding 35°C for 48–72 hours. Even if the peptide arrives with an ice pack, the ice pack may have melted 24+ hours earlier. This is why reputable suppliers use insulated shippers with gel packs or dry ice rated for the expected transit duration, and why tracking data showing <48-hour transit time matters as much as the peptide's stated purity.

Real Peptides ships all lyophilised peptides, including VIP, in insulated packaging with temperature-monitoring indicators. If a package is delayed in transit beyond the gel pack's effective window, we reship at no cost. The financial loss of replacing a shipment is far smaller than the reputational cost of delivering degraded material that produces null results in a researcher's assay.

Upon receipt, lyophilised VIP should be stored immediately at −20°C or colder. Do not store at 2–8°C (refrigerator) for more than 72 hours. The lyophilised powder is hygroscopic and will absorb atmospheric moisture even through sealed vial stoppers, initiating slow hydrolysis. For long-term storage (>6 months), −80°C is preferred.

Reconstitution protocol: Use sterile bacteriostatic water or 0.9% saline. Inject the solvent slowly down the vial wall, not directly onto the peptide cake. Direct injection can denature surface residues through shear force. Swirl gently to dissolve; do not vortex. Aliquot immediately into cryovials (50–100 µL per tube for single-use doses) and freeze at −80°C. Avoid repeated freeze-thaw cycles. Each cycle reduces activity by 5–10%. Thaw aliquots at 2–8°C (refrigerator), not room temperature or warm water bath, which creates thermal gradients that accelerate aggregation.

VIP for Sale: Research Peptide Purity Comparison

Researchers evaluating VIP for sale across suppliers face inconsistent documentation standards, variable synthesis quality, and significant price differences that don't always correlate with actual purity. The table below compares key quality indicators across typical supplier tiers.

The Professional Assessment column reflects real-world reproducibility outcomes. Research-grade suppliers like Real Peptides occupy the cost-benefit sweet spot: institutional-quality peptides at prices that allow repeated experiments without budget constraints forcing researchers into lower-quality alternatives that compromise data integrity.

Price alone is not a reliable quality indicator. Some mid-tier suppliers charge premium prices while providing generic CoAs and ambient shipping. Conversely, extremely low prices (<$40/vial for a 28-residue peptide) signal synthesis shortcuts: lower coupling efficiency, no post-synthesis purification, or improper folding. The downstream cost is failed experiments, wasted animal models, and irreproducible findings.

Key Takeaways

• VIP for sale in research markets refers to lyophilised Vasoactive Intestinal Peptide synthesized to exact 28-amino-acid sequences for laboratory investigation, not clinical use.
• VIP activates VPAC1/VPAC2 receptors to elevate cAMP, shifting immune responses toward anti-inflammatory Treg phenotypes and reducing IL-17 and TNF-α in animal models.
• Synthesis precision is critical: improper disulfide bond formation creates peptides with correct molecular weight but non-functional three-dimensional structure and reduced receptor binding.
• HPLC purity >98% with batch-specific chromatograms and mass spectrometry confirmation are minimum documentation standards for reproducible research.
• VIP degrades 10–15% per week at refrigerator temperatures (2–8°C) after reconstitution; aliquot and store at −80°C to preserve bioactivity.
• Cold-chain shipping failures cause irreversible peptide degradation even if samples are refrozen after ambient exposure. Verify suppliers use insulated packaging with transit-appropriate cooling.
• Real Peptides provides VIP with ESI-MS verification, batch-specific CoAs, and cold-chain shipping as standard, ensuring the peptide quality matches published research protocols.

What If: VIP Research Scenarios

What If My Reconstituted VIP Was Left at Room Temperature for 12 Hours?

Discard the vial and order a replacement. VIP loses 20–40% bioactivity after 12 hours at ambient temperature due to methionine oxidation and peptide bond hydrolysis. The degradation is irreversible and there is no reliable way to quantify remaining potency without receptor-binding assays. Using compromised peptide introduces a confounding variable that invalidates experimental results, particularly in dose-response studies where reduced activity could be misinterpreted as biological effect rather than material failure. The cost of replacing a single 2mg vial ($85–$120) is negligible compared to the cost of repeating an entire study with failed controls.

What If the Supplier Cannot Provide Batch-Specific Mass Spec Data?

Request it explicitly before purchase, and if unavailable, source VIP from a different supplier. Mass spectrometry confirmation is not optional for research peptides. It verifies that the synthesized molecule matches the intended amino acid sequence and that no truncated or modified peptides are present above trace levels. Suppliers who claim proprietary synthesis methods prevent data sharing or offer only generic purity percentages are either using third-party manufacturers they cannot vouch for or are reselling material of unknown provenance. Legitimate research suppliers like Real Peptides provide ESI-MS traces specific to each production lot because this is standard quality assurance in peptide manufacturing, not a premium service.

What If I Need VIP for a Multi-Week Study with Daily Dosing?

Aliquot the reconstituted peptide into single-use volumes (e.g., 50 µL per tube for one day's injections) and store at −80°C. Thaw one aliquot per day in the refrigerator 30 minutes before use and discard any unused volume after 24 hours. Do not refreeze. This protocol eliminates repeated freeze-thaw cycles on your stock solution, which fragment peptides and reduce titer over time. For a 28-day study with daily injections, you would aliquot 28 tubes from one reconstituted vial, keeping your working stock stable throughout the experimental timeline.

What If My Institution Requires GMP-Grade Peptides?

VIP for research is manufactured under good laboratory practice (GLP) standards, not GMP (good manufacturing practice), which applies to pharmaceutical production for clinical trials or marketed drugs. If your institutional biosafety or IACUC protocol mandates GMP, you will need to source VIP from a custom synthesis house that holds FDA registration as a contract manufacturer. These facilities charge significantly more ($300–$600 per vial) because they maintain cleanroom environments, validated production processes, and batch release testing that exceeds research-grade requirements. Most academic animal research protocols accept GLP-grade peptides; GMP is typically required only for IND-enabling toxicology studies or human pilot trials.

The Research-Grade Truth About VIP for Sale

Here's the honest answer: most failures in VIP research trace back to peptide quality, not experimental design. The published literature on VIP's immunomodulatory and neuroprotective effects is robust, and the mechanisms are well-characterized. VPAC receptor activation, cAMP elevation, Treg induction, and cytokine modulation are reproducible across laboratories when peptide integrity is maintained. When a researcher cannot replicate those findings, the first question should not be 'Did I design the protocol wrong?' but 'Is my VIP actually functional?'

The reality is that VIP synthesis is technically demanding. A 28-residue peptide with six disulfide bonds requires near-perfect coupling efficiency and controlled oxidative folding. Shortcuts at either stage produce material that looks correct on a certificate of analysis but behaves incorrectly in vivo. Budget suppliers who undercut research-grade pricing by 40–60% are not performing magic; they are accepting lower coupling yields, skipping purification steps, or selling material that passed mass spec but failed functional assays.

We have worked with labs who switched to Real Peptides after months of null results with cheaper alternatives, only to see their positive controls finally behave as literature predicts. The amino acid sequence was identical between suppliers. The three-dimensional structure was not. If your VIP isn't working, the peptide is almost certainly the problem, not your mice, your injection technique, or your experimental timeline.

When VIP is offered for sale at prices that seem too good to be true, they are. Peptide synthesis has fixed costs: resin, protected amino acids, HPLC columns, lyophilisation equipment, and most importantly, the expertise to execute 28 coupling cycles without error. Suppliers selling VIP for $35/vial are either diluting the peptide, providing crude (unpurified) synthesis products, or operating with such low quality control that batch-to-batch consistency is non-existent. Reproducible research cannot be built on variable raw materials.

VIP for sale from Real Peptides carries the documentation, handling, and synthesis precision that institutional research demands because we understand that failed experiments cost far more than the marginal difference between a $50 vial and a $100 vial. One contaminated batch or improperly stored shipment can set a dissertation timeline back by months. And no graduate student or lab manager needs that.

The scientific method depends on controlling variables. When your peptide is a variable, your results are meaningless. That's not an opinion. It's a statement about experimental validity. Choose VIP suppliers who treat peptide manufacturing as precision biochemistry, not commodity chemical sales, and your research outcomes will reflect that choice in reproducibility and alignment with published data.

If VIP receptor-mediated pathways are central to your model. Whether studying autoimmune regulation, neuroinflammation, or pulmonary fibrosis. The peptide is not the place to cut corners. We synthesize every batch of VIP as if it were going into our own lab, with the same documentation and cold-chain protocols we would demand if the roles were reversed. That standard has earned us partnerships with research institutions who cannot afford to repeat experiments because a supplier shipped degraded material to save three dollars on shipping ice.

FAQs

[
{
"question": "What is VIP peptide used for in research?",
"answer": "VIP (Vasoactive Intestinal Peptide) is used in laboratory research to study immunomodulation, neuroprotection, and smooth muscle physiology. It activates VPAC1 and VPAC2 receptors to elevate cAMP, which shifts T-cell populations toward regulatory phenotypes, reduces pro-inflammatory cytokines like IL-17 and TNF-α, and relaxes bronchial smooth muscle. Research applications include animal models of rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, traumatic brain injury, asthma, and pulmonary fibrosis. VIP is not approved for clinical use in humans and is supplied exclusively for in vitro or animal studies."
},
{
"question": "Can I use VIP for sale for human clinical applications?",
"answer": "No. VIP for sale from research peptide suppliers is manufactured for laboratory research only and is not FDA-approved for human use. These preparations are synthesized under good laboratory practice (GLP) standards, not the good manufacturing practice (GMP) standards required for clinical trials or therapeutic administration. Research-grade peptides lack the sterility validation, endotoxin testing, and batch release requirements mandated for injectable drugs. Using research peptides in humans violates federal regulations and poses significant safety risks. Clinical-grade VIP would require sourcing from an FDA-registered pharmaceutical manufacturer under an Investigational New Drug (IND) application."
},
{
"question": "How much does research-grade VIP cost?",
"answer": "Research-grade VIP typically costs $85–$120 per 2mg vial when purchased from suppliers who provide batch-specific purity documentation and cold-chain shipping. Mid-tier suppliers charge $60–$85 but often lack verified mass spectrometry or consistent handling protocols. Budget suppliers offer VIP for $30–$50 per vial, but these preparations frequently show lower purity (<95%), no analytical verification, and significant batch-to-batch variation that compromises experimental reproducibility. Custom synthesis houses serving pharmaceutical clients charge $200–$400+ per vial with comprehensive analytical packages, but this is cost-prohibitive for most academic research."
},
{
"question": "What purity level should I expect when VIP is for sale?",
"answer": "Research-grade VIP should be >98% pure as measured by HPLC (high-performance liquid chromatography), with a batch-specific chromatogram showing a single dominant peak and minimal impurity signals. The supplier should also provide mass spectrometry confirmation that the molecular weight matches human VIP (3326.77 Da) and amino acid analysis verifying residue composition. Purity below 95% indicates incomplete purification or synthesis errors, which reduce receptor binding affinity and introduce confounding variables into dose-response experiments. Real Peptides provides VIP at >98% purity with ESI-MS verification and HPLC chromatograms included in every certificate of analysis."
},
{
"question": "How do I store VIP peptide after reconstitution?",
"answer": "After reconstitution with bacteriostatic water or sterile saline, immediately aliquot VIP into single-use volumes (50–100 µL per cryovial) and freeze at −80°C. Do not store reconstituted VIP at 2–8°C (refrigerator) for more than 24 hours. It degrades approximately 10–15% per week at that temperature. Avoid repeated freeze-thaw cycles, which fragment peptide bonds and reduce bioactivity by 5–10% per cycle. Thaw aliquots at refrigerator temperature (2–8°C) immediately before use, never at room temperature or in a warm water bath. Lyophilised VIP before reconstitution should be stored at −20°C or colder in a sealed vial with desiccant."
},
{
"question": "What is the difference between VIP and VIP analogs?",
"answer": "Native VIP is the 28-amino-acid human sequence (HSDAVFTDNYTRLRKQMAVKKYLNSILN) with natural disulfide bonds and methionine residues. VIP analogs are synthetic variants with substitutions designed to improve stability or receptor selectivity. Common modifications include replacing methionine at position 17 with norleucine to prevent oxidation, or truncating the C-terminus to create shorter fragments. Analogs may show altered receptor affinity (preferential VPAC1 vs VPAC2 binding) or extended half-life due to protease resistance. When VIP is listed for sale, confirm whether it is native sequence or an analog, as biological activity and literature comparisons depend on exact structure."
},
{
"question": "How is VIP synthesized for research use?",
"answer": "VIP is synthesized using solid-phase peptide synthesis (SPPS) with Fmoc chemistry, where amino acids are sequentially coupled to a resin-bound chain over 28 cycles. After cleavage from the resin, the linear peptide undergoes controlled oxidation (air oxidation or iodine) to form six disulfide bonds in the correct pairings. The crude peptide is then purified via reverse-phase HPLC to remove truncated sequences and misfolded variants, achieving >98% purity. Final product is verified by mass spectrometry (confirming molecular weight 3326.77 Da) and amino acid analysis before lyophilisation. High-quality synthesis requires near-perfect coupling efficiency and proper folding conditions. Errors at either stage produce non-functional peptides."
},
{
"question": "Why does VIP for sale vary so much in price?",
"answer": "Price variation reflects differences in synthesis quality, purification rigor, analytical verification, and handling protocols. Research-grade suppliers like Real Peptides synthesize VIP in small batches with HPLC purification, ESI-MS verification, and cold-chain shipping, which adds cost but ensures reproducible results. Budget suppliers reduce expenses by accepting lower coupling yields (producing more impurities), skipping post-synthesis purification, providing generic certificates without batch-specific data, or using ambient shipping that degrades peptides in transit. A $35 vial may contain 90% VIP plus 10% truncated sequences and misfolded variants, while a $100 vial contains >98% correctly folded peptide. The functional difference in receptor binding can exceed 50%, making the cheaper option a false economy."
},
{
"question": "Does Real Peptides provide certificates of analysis for VIP?",
"answer": "Yes. Every batch of VIP sold by Real Peptides includes a certificate of analysis (CoA) with batch-specific HPLC chromatogram and electrospray ionization mass spectrometry (ESI-MS) trace. The CoA confirms >98% purity, verifies the molecular weight matches human VIP (3326.77 Da), and documents synthesis and testing dates for traceability. This is standard quality assurance for research peptides and allows researchers to validate material identity before beginning experiments. Suppliers who provide only generic CoAs without analytical data or batch lot numbers cannot verify that the shipped material matches the documented specifications."
},
{
"question": "What happens if VIP is exposed to heat during shipping?",
"answer": "Heat exposure causes irreversible degradation through methionine oxidation, asparagine deamidation, and peptide bond hydrolysis. Even if the peptide is refrozen immediately after delivery, the structural damage cannot be reversed. A single 24-hour exposure to 25°C (room temperature) reduces VIP bioactivity by 20–40%, and exposure to 35°C (common in summer ground shipping) accelerates degradation further. This is why cold-chain shipping with insulated packaging and temperature-appropriate gel packs or dry ice is non-negotiable for peptide stability. Real Peptides ships all lyophilised peptides in insulated containers rated for expected transit duration and will reship at no cost if tracking data shows delays beyond the cooling window."
},
{
"question": "Can I purchase VIP for sale without institutional affiliation?",
"answer": "Most research peptide suppliers, including Real Peptides, require institutional affiliation verification (university, research institute, or licensed laboratory) before processing VIP orders because these products are intended exclusively for supervised laboratory research, not personal use. Verification typically involves providing an institutional email address, lab registration number, or purchase order on institutional letterhead. This policy exists to prevent misuse of research compounds and to ensure peptides are handled by trained personnel with appropriate biosafety protocols. Individual researchers not affiliated with a recognized institution should contact suppliers directly to discuss eligibility and documentation requirements."
}
]
}